Good morning, folks. A busy week of deals across the medical devices and biotechnology sectors. Here are the top headlines I found. News from neuroscience, bioelectronics, diabetes care, and more. Congratulations to everyone involved.
➡️Salvia BioElectronics nets $60M to develop minimally invasive migraine implant
➡️Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B with Evopoint Biosciences
➡️PHASE Scientific raises $34M for urine test platform spanning cancer, women’s health and more
➡️Medtronic to spin out diabetes division as $2.8B independent player
➡️New York-based Grin Therapeutics, a developer of therapies to treat serious neurodevelopmental disorders, closed on $140 million in Series D funding
➡️Indianapolis-based Syndeio Biosciences, a developer of precision neurotherapeutics for central nervous system diseases, announced its launch this week in conjunction with securing over $90 million from a syndicate of life science investors.
➡️Vima Therapeutics, a Cambridge, Massachusetts-based startup focused on oral therapies for movement disorders announced its launch this week, along with $60 million in Series A financing led by Atlas Venture
➡️TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing rights to the China biotech’s T-cell engager designed to treat metastatic prostate cancer.
➡️Big Pharma-backed GlycoEra counting days to clinic with $130M raise for protein degraders
➡️Norwegian start-up Mycelium A/S bags €1.25m to scale mycoprotein production
➡️C4X Discovery Holdings Ltd has received a €8m milestone payment from the French pharmaceutical company Sanofi for its preclinical IL-17A inhibitor.
➡️Sanofi inks $470M Vigil Neurosciences buyout, brushing off rivals’ failures to join Novartis in Alzheimer’s race
➡️Acclaro Medical secures $23m in Series B funding for skin laser technologies
➡️ProteinQure Inc., a biotechnology company pioneering computational peptide therapeutics, announced today the close of an $11 million Series A financing round
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.
